CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 15 No. 11
 

CT Screening Detects Curable Stage I Lung Cancer

November 1, 2006

NEW YORK—Spiral CT screening of high-risk individuals could prevent about 80% of deaths from lung cancer, according to the latest results from the large collaborative I-ELCAP trial. “In our study, the estimated 10-year lung-cancer- specific survival rate among the 484 participants with disease diagnosed on CT, regardless of the stage at diagnosis or type of treatment, was 80%,” said Claudia I. Henschke, MD, of Weill Medical College of Cornell University, leader of the International Early Lung Cancer Action Program (I-ELCAP). Dr. Henschke and her colleagues reported the results in a recent issue of the New England Journal of Medicine (355:1763-1771, 2006).

In the study, screening was defined according to the I-ELCAP protocol allowing data from the participating institutions to be pooled. Further, I-ELCAP provided a management algorithm for baseline CT and repeated CT screening.

Participants were at least 40 years of age and were at risk for lung cancer due to a history of cigarette smoking, occupational exposure, or exposure to secondhand smoke (with the exception of patients from Azumi, Japan, who participated as part of their annual health screening program).

Between 1993 and 2005, a total of 31,567 asymptomatic men and women underwent baseline CT screening. From 1994 to 2005, a total of 27,456 annual CT screenings were conducted. Biopsies as recommended by the protocol were performed in 535 participants, and 492 were diagnosed with malignant disease (479 lung cancers). Of these 479 lung cancers, 405 were found at baseline and 74 at an annual screening. Another 5 were defined as interim diagnoses, prompted by the development of symptoms within 12 months of the baseline screening.

Of the 484 participants diagnosed with lung cancer, 411 had surgery; 57 received radiation, chemotherapy, or both; and 16 received no treatment. Two patients died within 4 weeks after surgery, for an operative mortality rate of 0.5%.

Among the 412 participants (85%) with clinical stage I lung cancer found by CT screening, the estimated 10-year survival rate was 88%. This rose to 92% among the 302 patients with clinical stage I disease who had surgical resection within 1 month of their diagnosis. All 8 untreated patients with stage I disease died within 5 years of diagnosis.

Comparison to Mammography Dr. Henschke compared the results with those of breast cancer screening. “For lung cancer, the rates of detection among the participants in the study who were 40 years of age and older were 1.3% on baseline CT screening and 0.3% on annual screening, values that were slightly higher than those for the detection of breast cancer on baseline screening (0.6% to 1%) and similar to those for annual screening (0.2% to 0.4%), among women 40 years of age and older,” she said.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

A ‘Sweat Equity’ Study
Commenting on the study, James Mulshine, MD, of Rush University Medical Center, Chicago, said that “a remarkable aspect of this study is that it was largely conducted by sweat equity.” While the group did receive funding from the NCI and other organizations, he said, “the vast majority of the IELCAP research was conducted by the voluntary efforts of the investigators.” This involved hundreds of professionals along with the tens of thousands of study participants from across the world. Their motivation, he said, was “a fervent desire to finally demonstrate that we can routinely cure even the world’s most feared cancer.”

Counter Point
I-ELCAP Results ‘Provocative, Welcome,’ But Randomized Studies Are on the Horizon

MICHAEL UNGER, MD — In a New England Journal of Medicine editorial, Dr. Unger, of the Pulmonary Cancer Detection and Prevention Program, Fox Chase Cancer Center, called the I-ELCAP study “a provocative, welcome salvo in the long struggle to reduce the tremendous burden of lung cancer on society.” He praised the trial for being conducted in both academic institutions and community hospitals, “thereby demonstrating adaptability in various health care delivery systems.”

Dr. Unger also pointed out the most obvious problem with the lung screening study—that it was a “systematic case-control observational study, not the gold-standard randomized trial.” Nevertheless, he said, before the I-ELCAP study, “we lacked documentation of the results of a detection test combined with planned management and long-term followup. Previous information was based in large part on incidental rather than methodically collected findings in lung cancer.”

Important problems with the study, Dr. Unger said, include the possibility that lead time biases and overdiagnosis could have affected mortality results, the fact that CT scans alone do not show differences between tumors and growing granulomatous lesions, and that centrally located tumors or tumors in the airway are not readily found by CT.

He noted that NIH and the Mayo Clinic are both conducting randomized lung screening studies that should provide a more definitive answer as to the value of CT chest screening in high-risk populations.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy